Overview of Gemcitabine Activity in Advanced Breast Cancer

Smith, Ian

doi:10.1053/j.seminoncol.2006.03.020

Cited by 14 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously reported treatment response rates of gemcitabinecisplatin combination chemotherapy have been variable, ranging from 26∼80% (2,8,15,16). For patients with metastatic breast cancer pretreated with anthracycline and taxane, a response rate of 34.3%, a median OS of 13.5 months and a TTP of 6.0 months have been reported (15).…”

Section: Discussionmentioning

confidence: 99%

Phase II Study of Gemcitabine plus Cisplatin in Patients with Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer

Kim

Kwon

et al. 2008

Cancer Res Treat

View full text Add to dashboard Cite

Purpose: Metastatic breast cancer patients are usually exposed to taxane and anthracycline as neoadjuvant, adjuvant and palliative chemotherapeutic agents. This study was designed to determine the efficacy and safety of the use of a gemcitabine and cisplatin (GP) combination treatment in patients with metastatic breast cancer that were pretreated with anthracycline and taxane. Materials and Methods:We evaluated the use of a GP regimen (1,000 mg/m 2 gemcitabine administered on days 1 and 8 plus 60 mg/m 2 cisplatin administered on day 1 every 3 weeks) in 38 breast cancer patients who had received prior chemotherapy with anthracycline and taxane as an adjuvant or neoadjuvant therapy, or as a palliative therapy.Results

show abstract

Section: Discussionmentioning

confidence: 99%

Phase II Study of Gemcitabine plus Cisplatin in Patients with Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer

Kim

Kwon

et al. 2008

Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Several agents, including gemcitabine, docetaxel, and capecitabine, have single-agent activity in advanced breast cancer [6][7][8]. Relative to single-agent therapy, combinations can significantly improve time to progression (TTP) and response, with a small increase in overall survival (OS) [9].…”

Section: Introductionmentioning

confidence: 99%

A Pooled Analysis of Gemcitabine Plus Docetaxel Versus Capecitabine Plus Docetaxel in Metastatic Breast Cancer

Seidman

Chan²,

Wang

et al. 2014

The Oncologist

View full text Add to dashboard Cite

Introduction. In two randomized phase III trials of patients with metastatic breast cancer (MBC), gemcitabine-docetaxel (GD) and capecitabine-docetaxel (CD) had similar efficacy, but distinct safety profiles. Methods. Data from two GD versus CD studies were pooled; overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) were determined. Cox proportional hazards models identified prognostic factors associated with improved OS and PFS. Using a multivariate prognostic model incorporating identified adverse prognostic factors, we grouped MBC patients into low-, intermediate-, and high-risk categories. Hazard ratios (HRs) of GD over CD for OS and PFS were determined for subsets of patients.Results. Baseline demographics of the pooled population were mostly well balanced. In the pooled population, there

show abstract

“…Gemcitabine1 (Fig. 1), 2′,2′‐difluoro‐2′‐deoxycytidine (dFdC), is a pyrimidine antimetabolite, with a broad spectrum of antitumor activity, employed against several human malignancies such as ovarian, lung, pancreatic, bladder, breast and urothelial cancer 2–6…”

Section: Introductionmentioning

confidence: 99%

Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non‐small‐cell lung cancer by high‐performance liquid chromatography‐tandem mass spectrometry

et al. 2007

View full text Add to dashboard Cite

Gemcitabine, 2',2'-difluoro-2'-deoxycytidine (dFdC) is a pyrimidine antimetabolite employed against several human malignancies. It undergoes intracellular activation to the pharmacologically active triphosphate form (dFdCTP) and metabolic inactivation to the metabolite 2',2'-difluorodeoxyuridine (dFdU). In order to investigate the human plasma pharmacokinetics of dFdC and dFdU, we developed and validated an HPLC-MS/MS method, adding 2'-deoxycytidine as internal standard and simply precipitating the protein with acetonitrile. The method requires a small sample (125 microl), and it is rapid and selective, allowing good resolution of peaks from the plasma matrix in only 7 min. It is sensitive, precise and accurate, with overall precision, expressed as CV%, always less than 10.0% for both analytes and high recovery: > or = 80%. The limits of detection for dFdC and dFdU were 0.1 and 1.1 ng/ml, but considering the high concentrations in the plasma of patients investigated, we set the limit of quantitation at 20 ng/ml (0.08 microM) for dFdC and 250 ng/ml for dFdU, and validated the assay up to the dFdC concentration of 6.0 microg/ml (22.8 microM). The method was successfully used to study the drug pharmacokinetics in patients with advanced non-small-cell lung cancer in a phase II trial with gemcitabine administered as a fixed dose-rate infusion.

show abstract

Overview of Gemcitabine Activity in Advanced Breast Cancer

Cited by 14 publications

References 11 publications

Phase II Study of Gemcitabine plus Cisplatin in Patients with Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer

Phase II Study of Gemcitabine plus Cisplatin in Patients with Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer

A Pooled Analysis of Gemcitabine Plus Docetaxel Versus Capecitabine Plus Docetaxel in Metastatic Breast Cancer

Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non‐small‐cell lung cancer by high‐performance liquid chromatography‐tandem mass spectrometry

Contact Info

Product

Resources

About